1-6 of 6
Julia Marx
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of the Astral Study: A Prospective Phase II Clinical Study of the German Lymphoma Alliance to Assess the Efficacy and Toxicity of High-Dose Chemotherapy Followed By Allogeneic Stem Cell Transplantation As Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Bertram Glass, Bettina Altmann, Matthias Stelljes, Georg Lenz, Julia Marx, Justin Hasenkamp, Frank P. Kroschinsky, Anna Ossami Saidy, Peter Dreger, Lutz Peter Hermann Mueller, Inken Hilgendorf, Gerald Illerhaus, Guido Kobbe, Roland Schroers, Katrin Linke, Carsta Koehler, Norbert Schmitz, Marita Ziepert, Pearl van Heteren
Journal: Blood
Blood (2023) 142 (Supplement 1): 231.
https://doi.org/10.1182/blood-2023-173179
Published: 2023
Journal Articles

Blast Clearance after High Dose-Melphalan Conditioning for Allogeneic Stem Cell Transplantation in Relapsed and Refractory Acute Myeloid Leukemia

Julian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, Lina Kolloch, Philipp Berning, Simon Call, Matthias Floeth, Julia Marx, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes
Journal: Blood
Blood (2023) 142 (Supplement 1): 4911.
https://doi.org/10.1182/blood-2023-180723
Published: 2023
Journal Articles

Comparable Survival for Fludarabine and Treosulfan Vs. Fludarabine and TBI As Conditioning Regimens in Patients with AML and MDS Undergoing Allogeneic Stem Cell Transplantation

Lina Kolloch, Philipp Berning, Christian Reicherts, Simon Call, Julia Marx, Matthias Floeth, Eva Esseling, Julian Ronnacker, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes
Journal: Blood
Blood (2023) 142 (Supplement 1): 3535.
https://doi.org/10.1182/blood-2023-180078
Published: 2023
Journal Articles

Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease

Matthias Floeth, Elena Beckmann, Christian Reicherts, Julia Marx, Simon Call, Inna Shaforostova, Eva Eßeling, Jorn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Georg Lenz, Matthias Stelljes
Journal: Blood
Blood (2022) 140 (Supplement 1): 7587–7588.
https://doi.org/10.1182/blood-2022-165424
Published: 2022
Journal Articles

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Matthias Stelljes, Nael Alakel, Ralph Wäsch, Sebastian Scholl, Kathrin Nachtkamp, Andreas Rank, Mathias Haenel, Bernd Spriewald, Maher Hanoun, Sonja Martin, Katjana Schwab, Julian Knaden, Lena Reiser, Julia Marx, Klaus Wethmar, Tim Sauer, Wolfgang E. Berdel, Georg Lenz, Monika Brüggemann, Simon Raffel, Nicola Goekbuget
Journal: Blood
Blood (2022) 140 (Supplement 1): 510–512.
https://doi.org/10.1182/blood-2022-162235
Published: 2022
Journal Articles

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Matthias Stelljes, Nael Alakel, Ralph Wäsch, Sebastian Scholl, Kathrin Nachtkamp, Andreas Rank, Mathias Haenel, Bernd Spriewald, Maher Hanoun, Sonja Martin, Katjana Schwab, Julian Knaden, Julia Marx, Klaus Wethmar, Tim Sauer, Wolfgang E. Berdel, Georg Lenz, Martin Dugas, Nicola Goekbuget, Monika Brueggemann, Simon Raffel
Journal: Blood
Blood (2021) 138 (Supplement 1): 2300.
https://doi.org/10.1182/blood-2021-145553
Published: 2021